Loading clinical trials...
Loading clinical trials...
A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Lopinavir/Ritonavir (Kaletra), to Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) Plus Lopinavir/Ritonavir (Kaletra) in Adult HIV-1 Infected Subjects With Raised Cholesterol
Conditions
Interventions
Truvada + Kaletra
Kivexa + Kaletra
Locations
4
Austria
Gilead Sciences
Vienna, Austria
Gilead Sciences
Munich, Germany
Gilead Sciences
Milan, Italy
Gilead Sciences
Madrid, Spain
Start Date
October 1, 2008
Primary Completion Date
September 1, 2009
Completion Date
October 1, 2009
Last Updated
November 21, 2011
NCT07055451
NCT05136703
NCT05668026
NCT04174755
NCT06691321
NCT06631365
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions